SEC Form 4 · accession 0001231919-26-000859
Braveheart Bio, Inc. · BRVE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Marc L Andreessen
10% Owner
Benjamin A Horowitz
10% Owner
AH Bio Fund IV, L.P.
10% Owner
AH Equity Partners Bio IV, L.L.C.
10% Owner
Period of report
Aug 7, 2026
Accepted (ET)
Aug 11, 2026 · 5:53 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002131524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Aug 7, 2026 | C | 9,132,420 | — | A | 9,132,420 | I | By AH Bio Fund IV, L.P. |
| Common StockF2,F3 | Aug 7, 2026 | P | 1,100,000 | $18.00 | A | 10,232,420 | I | By AH Bio Fund IV, L.P. |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Preferred StockF2,F3,F1 | — | Aug 7, 2026 | C | 40,000,000 | D | — | — | Common Stock | 9,132,420 | 0 | I |
Explanation of responses
- F1Series A Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 4.38-for-1 basis. The Series A Preferred Stock had no expiration date.
- F2The reported securities are held by AH Bio Fund IV, L.P. ("AH Bio Fund IV"), for itself and as nominee for AH Bio Fund IV-B, L.P., AH 2022 Annual Fund, L.P., AH 2022 Annual Fund-B, L.P., AH 2022 Annual Fund-QC, L.P. and CLF Partners III, LP. AH Equity Partners Bio IV, L.L.C. ("AH EP Bio IV") is the general partner of AH Bio Fund IV and has sole voting and dispositive power with regard to the securities held by AH Bio Fund IV for itself and as nominee. The managing members of AH EP Bio IV are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund IV for itself and as nominee.
- F3(Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held by AH Bio Fund IV for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.